إعلان مُمول
Novo Nordisk launches Wegovy in India, targets obesity treatment market, offers semaglutide-based weekly injection
نشر بتاريخ
Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 and Rs 26,050 per month, the injectable drug targets India's large obese population. The company aims to create awareness and collaborate with stakeholders to combat obesity, citing its significant impact on India's GDP.
البحث
الأقسام
- National
- International
- Business
- Technology
- Health
- التعليم
- Sports
- Entertainment
- Travel
- Environment
- Science
- Law
- Agriculture
- Real Estate
- Opinion
- Religion
- Weather
- Automotive
- Social Issues
- Culture
- Sci-Fi & Future
إقرأ المزيد
Nepal Rastra Bank revises foreign exchange rates for Wednesday
KATHMANDU: The Nepal Rastra Bank (NRB) has released the official foreign currency exchange rates...
‘Dear Donald’: Trump posts Nato chief’s praise amid Hague summit trip; calls action against Iran ‘extraordinary’ and bold
President Trump shared messages from Nato secretary-general Rutte, lauding Trump's actions in...